Optimising GDMT Post AHF Discharge – APAC APSC Consensus Highlights

This section presents a concise, high-yield summary of the video’s core content, designed as a quick reference for Healthcare Professionals (HCPs).

Note: This content was developed by our editorial team and was not reviewed or endorsed by the video speaker.

Q1. Why is hospitalisation for HF a critical therapeutic window?
Because the period immediately following acute decompensation carries a disproportionately high risk of death and re-hospitalisation. Initiating GDMT during this phase modifies risk earlier than delayed outpatient initiation. [3,9]

Q2. What did STRONG-HF change in clinical thinking?
It demonstrated that structured, rapid uptitration with biomarker and safety monitoring is both feasible and beneficial, reframing GDMT as an urgent, protocol-driven intervention rather than a chronic maintenance regimen.[4,6]

Q3. How do biomarkers support rapid GDMT optimisation?
Serial NT-proBNP, blood pressure, potassium, and renal function help differentiate persistent congestion from haemodynamic limitation, guiding decisions on when to decongest versus intensify therapy.[4,7] 

Q4. How does the APSC consensus differ from other guidelines?
It maintains alignment with ESC/ACC/AHA guidelines but includes regional adaptations, such as more assertive use of MRAs in HFmrEF/HFpEF and extended titration timelines that reflect access constraints. [5,11]